ESMO: European Society for Medical Oncology

  1. LifeTime and RESTORE among shortlisted projects
  2. Axumin is a radiopharmaceutical agentfor functional imaging of prostate cancer recurrence
  3. Increase in accrual capacity and the quality standards
  4. Both contain the active substance pegfilgrastim and were developed as a biosimilar medicine
  5. Approval is based on results from the HERCULES trial